S. Krintel

发表

FRI0067 Changes in Multi-Biomarker Disease Activity (MBDA) Score Correlate with Changes in Established Disease Activity Measurements in Patients with Early Ra from The Opera Study

C. Brahe, P. Junker, N. Defranoux, 2016 .

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

M. Østergaard, K. Stengaard-Pedersen, H. C. Horn, 2014, Annals of the rheumatic diseases.

Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial

M. Østergaard, K. Stengaard-Pedersen, T. Ellingsen, 2018, The Journal of Rheumatology.

Placebo-controlled Clinical Trial Responding to Adalimumab plus Methotrexate vs Methotrexate Alone : A Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis

M. Østergaard, K. Stengaard-Pedersen, T. Ellingsen, 2017 .

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

M. Østergaard, K. Stengaard-Pedersen, H. C. Horn, 2013, Annals of the rheumatic diseases.

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)

M. Østergaard, K. Stengaard-Pedersen, T. Ellingsen, 2015, Annals of the rheumatic diseases.

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial

H. Bliddal, K. Stengaard-Pedersen, H. C. Horn, 2017, Clinical Rheumatology.

Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNF&agr; inhibitors in patients with rheumatoid arthritis

L. Essioux, R. Benayed, S. Germer, 2012, Pharmacogenetics and genomics.

Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects

H. Johnsen, M. Nyegaard, R. Steffensen, 2011, Arthritis research & therapy.

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

K. Stengaard-Pedersen, H. C. Horn, T. Ellingsen, 2015, The Pharmacogenomics Journal.

CD6 and Syntaxin Binding Protein 6 Variants and Response to Tumor Necrosis Factor Alpha Inhibitors in Danish Patients with Rheumatoid Arthritis

L. Essioux, M. Østergaard, A. Wool, 2012, PloS one.

Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans

S. Eyre, Jane Worthington, E. Flynn, 2013, PloS one.

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.

L. Essioux, G. Palermo, J. Johansen, 2013, Rheumatology.

Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNF&agr; inhibitors in patients with rheumatoid arthritis

L. Essioux, R. Benayed, S. Germer, 2012, Pharmacogenetics and genomics.

Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans

S. Eyre, E. Flynn, P. Dieudé, 2013, PLoS ONE.

University of Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in Europeans

S. Eyre, Jane Worthington, E. Flynn, 2013 .

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

M. Østergaard, K. Stengaard-Pedersen, H. C. Horn, 2013, Annals of the rheumatic diseases.

Response to Treatment With Tofacitinib in 11 Patients With Refractory Granulomatosis With Polyangiitis

B. Baslund, M. Faurschou, L. Linde, 2023, Journal of Rheumatology.